Chapter 44: Attention-Deficit Disorders

Attention-deficit/hyperactivity disorder represents the most frequently diagnosed behavioral condition in children across the United States, with prevalence ranging between 5 and 10 percent of the pediatric population. The chapter traces the historical development of ADHD from early clinical observations in 1902 through successive diagnostic revisions, culminating in the DSM-5 classification as a neurodevelopmental disorder with greater international alignment through ICD-11 criteria. The diagnostic framework identifies three distinct presentation patterns—predominantly inattentive type, predominantly hyperactive-impulsive type, and combined type—each characterized by symptom onset before age 12, persistence for a minimum of six months, and functional impairment across multiple life domains including academic, social, and family contexts. The etiology involves complex interactions among genetic predisposition with heritability estimates between 60 and 90 percent, neurobiological alterations affecting cortico-striatal-thalamic and frontoparietal circuits, and environmental contributors such as prenatal substance exposure and perinatal complications. Neurochemical dysfunction centers on dysregulation of dopaminergic and noradrenergic systems with emerging recognition of glutamatergic involvement, while neuroimaging consistently documents delayed cortical development and structural circuit abnormalities. Clinical manifestations encompass hyperactivity manifesting as persistent fidgeting and restlessness, impulsivity reflected in action without forethought and reward-seeking behavior, and inattentional symptoms including distractibility and organizational difficulties that compromise academic achievement and peer relationships. The disorder frequently co-occurs with learning disorders, oppositional defiant disorder, mood disturbances, anxiety, and autism spectrum conditions, complicating both diagnosis and treatment planning. Longitudinal evidence indicates that approximately 60 percent of children experience symptom persistence into adulthood, where the presentation shifts toward internal restlessness, chronic disorganization, and impaired occupational and interpersonal functioning. Treatment integration requires multimodal intervention combining pharmacological approaches with stimulant medications such as methylphenidate and amphetamines as first-line agents, nonstimulant alternatives including atomoxetine and alpha-two agonists, and comprehensive psychosocial strategies encompassing behavioral modification, parent training, cognitive-behavioral techniques, and educational accommodations to address the multifaceted impairments associated with this chronic neurodevelopmental condition.